On February 19th, 2014 Health Canada issued an information update regarding labeling changes in the fosamprenavir (Telzir™) product monograph. The update includes a strengthened warning to avoid co-administration of fosamprenavir with certain medications used for regulating the rhythm of the heart. This labeling change does not represent a new safety concern.
For more information: Click here to view the Health Canada advisory
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
